Thursday, February 9, 2012 Last update: 1:33 PM
The Best of U.S. Company Technology News
Now being accepted at FreshNews.com. See our complete guidelines.
Trade Events
Gilead Sciences, Inc.
News articles for Gilead Sciences, Inc.:
Thursday, February 2, 2012
- Gilead Sciences Announces Fourth Quarter and Full Year 2011 Financial ResultsGilead Sciences, Inc. (Nasdaq:GILD) announced today its results of operations for the fourth quarter and full year 2011. Total revenues for the fourth quarter of 2011 increased 10 ... read more
Thursday, January 26, 2012
- Gilead Sciences to Release Fourth Quarter and Year End 2011 Financial Results on Thursday, February 2, 2012Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its fourth quarter and year end 2011 financial results will be released on Thursday, February 2, at 4:05 p.m. Eastern Time. ... read more
Tuesday, January 24, 2012
- Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIVGilead Sciences, Inc. (Nasdaq: GILD) today announced the initiation of a Phase 2 clinical trial evaluating GS-7340 for the treatment of HIV-1 infection in treatment-naïve adults. GS-7340 is ... read more
Wednesday, January 18, 2012
- U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIVGilead Sciences, Inc. (Nasdaq:GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved Viread® (tenofovir disoproxil fumarate) in combination with other antiretroviral agents for ... read moreRoy D. Baynes, MD, PhD, to Join Gilead Sciences as Senior Vice President, Oncology TherapeuticsGilead Sciences, Inc. (Nasdaq:GILD) today announced that Roy D. Baynes, MD, PhD, will join the company as Senior Vice President, Oncology Therapeutics. In this position, Dr. Baynes will ... read more
Tuesday, January 17, 2012
- Gilead Sciences Completes Acquisition of Pharmasset, Inc.Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Royal Merger Sub II Inc., a wholly-owned subsidiary of Gilead (“Merger Sub II”), ... read more
Wednesday, January 11, 2012
- Gilead Sciences Completes Tender Offer for All Outstanding Shares of Pharmasset, Inc.Gilead Sciences, Inc. (Nasdaq:GILD) today announced the successful completion of the tender offer by its wholly-owned subsidiary, Royal Merger Sub II Inc. (“Merger Sub II”), for all of ... read more
Friday, January 6, 2012
- Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting PeriodGilead Sciences, Inc. (Nasdaq:GILD) today announced that it has received early termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with ... read more
Thursday, January 5, 2012
- Gilead Sciences to Present at the 30th Annual JPMorgan Healthcare Conference on Monday, January 9Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the 30th Annual JPMorgan Healthcare Conference in San Francisco. ... read more
Friday, December 23, 2011
- U.S. FDA Accepts New Drug Application for Gilead’s Once-Daily, Single-Tablet Quad HIV RegimenGilead Sciences, Inc. (Nasdaq: GILD) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the Quad, a ... read more
Tuesday, December 20, 2011
- Gilead Files European Marketing Application for the Quad, a Once-Daily Single-Tablet Regimen for the Treatment of HIV InfectionGilead Sciences, Inc. (Nasdaq:GILD) announced today that the Marketing Authorisation Application (MAA) for the Quad single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil ... read more
Thursday, December 15, 2011
- Gilead Sciences Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Truvada® for Reducing the Risk of Acquiring HIVGilead Sciences, Inc. (Nasdaq: GILD) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval ... read more
Friday, December 9, 2011
- Gilead Announces Two-Year Data From Pivotal Phase 3 Study of Elvitegravir, an Integrase Inhibitor for HIVGilead Sciences, Inc. (Nasdaq:GILD) today announced topline Phase 3 clinical trial results showing that elvitegravir, an integrase inhibitor being evaluated for the treatment of HIV-1 infection, was non-inferior ... read more
Thursday, December 8, 2011
- Gilead Sciences and World Health Organization Establish New Five-Year Initiative to Prevent Deaths from Visceral LeishmaniasisGilead Sciences, Inc. (Nasdaq:GILD) announced today that it will donate 445,000 vials of AmBisome® (amphotericin B liposome for injection) over five years to help the World Health Organization ... read more
Tuesday, December 6, 2011
- Gilead Prices $3.7 Billion of Senior Unsecured NotesGilead Sciences, Inc. (Nasdaq:GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.7 billion, in an underwritten, registered public offering, consisting of ... read more
Monday, December 5, 2011
- Gilead’s Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 StudyGilead Sciences, Inc. (Nasdaq: GILD) today announced that a Phase 3 clinical trial (Study 114) of its pharmacoenhancing or “boosting” agent cobicistat, which increases blood levels of certain ... read more
Monday, November 28, 2011
- Gilead Sciences to Present at the 23rd Annual Piper Jaffray Healthcare Conference on Tuesday, November 29Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the 23rd Annual Piper Jaffray Healthcare Conference in New York. ... read moreGilead Receives European Marketing Authorization for Eviplera®, a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve AdultsGilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for Eviplera® (emtricitabine/rilpivirine/tenofovir disoproxil), a complete once-daily single-tablet regimen for the ... read more
Tuesday, November 22, 2011
- Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
Gilead Sciences, Inc. (Nasdaq:GILD) and Pharmasset, Inc. (Nasdaq:VRUS) announced today that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash. The transaction, which values Pharmasset at approximately $11 billion, was unanimously approved by Pharmasset’s Board of Directors. Gilead plans to finance the transaction with cash on hand, bank debt and senior unsecured notes. The company expects the transaction, when completed, to ... read more
Tuesday, November 15, 2011
- Gilead Sciences Finalizes Agreement with Tibotec Pharmaceuticals to Develop and Commercialize a Single-Tablet Regimen of Prezista® with Emtriva®, GS 7340 and CobicistatGilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a license agreement with Tibotec Pharmaceuticals for the development and commercialization of a single-tablet regimen combining ... read more